ArticleMorbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)2019
Surveillance for Coccidioidomycosis - United States, 2011-2017.
Article in Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Article
- Disseminated Pulmonary Coccidioidomycosis Presenting as a Wedge-Shaped Necrotic Mass Mimicking Malignancy.Cureus · 2026Article
- Review
- Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions.Journal of fungi (Basel, Switzerland) · 2026Article
- Frequency and Duration of Diagnostic Delays Associated with Coccidioidomycosis and Risk Factors for Missed Diagnoses, United States.Emerging infectious diseases · 2026Article
- Hybrid histidine kinases and antifungal warfare in thermal dimorphic fungi.Antimicrobial agents and chemotherapy · 2026Review
- Regional Increases in Incidence of Coccidioidomycosis (Valley Fever) - Arizona, 2005-2022.MMWR. Morbidity and mortality weekly report · 2026Article
- Development and Optimization of Multi-Well Colorimetric Assays for Growth ofJournal of fungi (Basel, Switzerland) · 2025Article
- Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database.Open forum infectious diseases · 2025Article
- The Epidemiology of Coccidioidomycosis (Valley fever) and the Disease Ecology ofPathogens (Basel, Switzerland) · 2025Article
- Cavitary Pneumonia Causes in the Arid Landscapes of Southern Arizona.American journal of medicine open · 2025Article
- Proposed Relationships Between Climate, Biological Soil Crusts, Human Health, and in Arid Ecosystems.GeoHealth · 2025Review
- Overview of the Current Challenges in Pulmonary Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Clinical Characteristics and Mortality Risks Among Patients With Culture-Proven Coccidioidomycosis Who Are Critically Ill: A Multicenter Study in an Endemic Region.Open forum infectious diseases · 2024Article
- Coccidioides Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases.ACR open rheumatology · 2024Article
- Wake-up Call: Rapid Increase in Human Fungal Diseases under Climate Change.Environmental health perspectives · 2024Article
- The Known and Unknown "Knowns" of Human Susceptibility to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- A microbial risk assessor's guide to Valley Fever (Coccidioides spp.): Case study and review of risk factors.The Science of the total environment · 2024Review
- Clinical Presentation of Blastomycosis is Associated With Infecting Species, Not Host Genotype.Clinical medicine & research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
problem/conditionCoccidioidomycosis (Valley fever) is an infection caused by the environmental fungus Coccidioides spp., which typically causes respiratory illness but also can lead to disseminated disease. This fungus typically lives in soils in warm, arid regions, including the southwestern United States. REPORTING PERIOD: 2011-2017. DESCRIPTION OF SYSTEM: Coccidioidomycosis has been nationally notifiable since 1995 and is reportable in 26 states and the District of Columbia (DC), where laboratories and physicians notify local and state public health departments about possible coccidioidomycosis cases. Health department staff determine which cases qualify as confirmed cases according to the definition established by Council of State and Territorial Epidemiologists and voluntarily submit basic case information to CDC through the National Notifiable Diseases Surveillance System.
resultsDuring 2011-2017, a total of 95,371 coccidioidomycosis cases from 26 states and DC were reported to CDC. The number of cases decreased from 2011 (22,634 cases) to 2014 (8,232 cases) and subsequently increased to 14,364 cases in 2017; >95% of cases were reported from Arizona and California. Reported incidence in Arizona decreased from 261 per 100,000 persons in 2011 to 101 in 2017, whereas California incidence increased from 15.7 to 18.2, and other state incidence rates stayed relatively constant. Patient demographic characteristics were largely consistent with previous years, with an overall predominance among males and among adults aged >60 years in Arizona and adults aged 40-59 years in California.
interpretationCoccidioidomycosis remains an important national public health problem with a well-established geographic focus. The reasons for the changing trends in reported cases are unclear but might include environmental factors (e.g., temperature and precipitation), surveillance artifacts, land use changes, and changes in the population at risk for the infection. PUBLIC HEALTH ACTION: Health care providers should consider a diagnosis of coccidioidomycosis in patients who live or work in or have traveled to areas with known geographic risk for Coccidioides and be aware that those areas might be broader than previously recognized. Coccidioidomycosis surveillance provides important information about the epidemiology of the disease but is incomplete both in terms of geographic coverage and data availability. Expanding surveillance to additional states could help identify emerging areas that pose a risk for locally acquired infections. In Arizona and California, where most cases occur, collecting systematic enhanced data, such as more detailed patient characteristics and disease severity, could help clarify the reasons behind the recent changes in incidence and identify additional opportunities for focused prevention and educational efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.